Taiho Oncology, Inc.
Clinical trials sponsored by Taiho Oncology, Inc., explained in plain language.
A subsidiary of Otsuka Holdings focused on oncology treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Cancer cocktail shows promise in early trial Results expected Oct 2026 (estimated)
- New study checks if kidney disease affects cancer drug safety Results expected Dec 2026 (estimated)
- New targeted drug shows promise for rare bile duct cancer Results expected Dec 2026 (estimated)
- New study seeks safer dosing of cancer drug for patients with liver issues Results expected Dec 2026 (estimated)
- Cancer drug futibatinib gets a safety check in Long-Term rollover study Results expected Apr 2027 (estimated)
-
Promising lymphoma combo trial halted over safety issues
Disease control Stopped earlyThis study tested a new drug combination (tolinapant plus decitabine/cedazuridine) in 33 adults with a rare, hard-to-treat blood cancer called peripheral T-cell lymphoma that had returned or not responded to prior treatment. The goal was to find a safe dose and see if the combina…
Phase 1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Experimental lung cancer drug trial halted early – only 18 patients enrolled
Disease control Stopped earlyThis early-stage trial tested a new drug, TAS3351, in 18 people with advanced lung cancer that had a specific genetic change (EGFR mutation). The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early, so results are limited.
Phase 1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Bladder cancer drug combo trial halted early
Disease control Stopped earlyThis study tested a combination of two drugs, futibatinib and pembrolizumab, in 43 people with advanced or metastatic bladder cancer who could not receive standard chemotherapy. The goal was to see if the combo could shrink tumors and to check its safety. The trial was terminated…
Phase 2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Targeted drug combo shows promise for rare breast cancer subtype
Disease control Stopped earlyThis phase 2 trial tested the drug futibatinib (TAS-120), alone or with the hormone therapy fulvestrant, in people with metastatic breast cancer that has specific FGFR gene changes. The study aimed to see if the treatment could shrink tumors or slow cancer growth. However, the tr…
Phase 2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental cancer drug trial halted early
Disease control Stopped earlyThis early-stage trial tested a new drug called TAS2940 in 29 people with advanced solid tumors (like lung, breast, or brain cancer) that had specific genetic changes (EGFR or HER2). The goal was to find a safe dose and see if the drug could shrink tumors. The study was stopped e…
Phase 1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Cancer drug trial halted early – what happened?
Disease control Stopped earlyThis phase 2 trial tested the drug futibatinib in 115 people with advanced solid tumors or blood cancers that have specific FGFR gene changes. The goal was to see if the drug could shrink tumors or cause remission. The study was terminated early, so final results are not yet clea…
Phase 2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC